GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

Cellectis CLLS · USD

Health Care · US listing · 🇺🇸 United States

Compare

1.12

+4.67%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Cellectis

Its shares trade under the ticker CLLS. It has been listed since 7 February 2007. In the fiscal year to 31 December 2025, it reported revenue of $72.9m and a net loss of $67.6m. At that date it held total assets of $324.7m and shareholders' equity of $75.9m.

Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL). It also develops ALPHA3, targets Large B-Cell Lymphoma (LBCL); TRAVERSE, for the treatment of patients with advanced or metastatic clear cell renal cell carcinoma (RCC). In addition, the company Melanoma, for treatment of unresectable or metastatic melanoma. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
7 Feb 2007
Employees
222
Head office
8 RUE DE LA CROIX JARRY, PARIS, LLE-DE-FRANCE
Incorporated in
I0
Classification
Biological Products, (No Diagnostic Substances)
Filer status
Accelerated filer

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Cellectis SA develops gene-editing products like BALLI-01 for r/r ALL treatment in Health Care sector.
  • Cellectis SA's portfolio includes ALPHA3 targeting Large B-Cell Lymphoma (LBCL) in immuno-oncology.
  • Cellectis SA has 222 employees focused on clinical stage biotechnology in Health Care.

Weaknesses

  • Cellectis SA's clinical stage biotechnology requires significant funding for product development.
  • Cellectis SA's products are still in clinical stages without approved treatments yet.
  • Cellectis SA's focus on gene therapy may face regulatory challenges in Health Care.

Opportunities

  • Cellectis SA can expand its portfolio with new gene therapy product candidates in Health Care.
  • Cellectis SA may benefit from growing demand for immuno-oncology treatments in the US.
  • Cellectis SA could leverage its Paris headquarters for European market access in Health Care.

Threats

  • Cellectis SA faces competition from other biotech companies in the Health Care sector.
  • Cellectis SA's products may encounter delays in clinical trials for r/r ALL and B-NHL.
  • Cellectis SA's reliance on gene-editing technology could lead to safety concerns in Health Care.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.